Investigational drug · Phase 2
Icalcaprant
Also called: ABBV-1354, CVL-354
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "Icalcaprant"
First trial start
2025
Dec 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Icalcaprant", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bipolar I Disorder
- Bipolar II Disorder
- Major Depressive Disorder
Approved drugs for the same conditions: Depression (major depressive disorder) · Bipolar disorder · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "Icalcaprant" as an intervention, largest first.
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive DisorderPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07276997 · 195 participants (planned) · Start Dec 18, 2025 · Primary completion Sep 2027
Drug: Icalcaprant; Placebo for Icalcaprant · For: Major Depressive Disorder
Sites: Dothan, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 33 sites in all
- A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II DisorderPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06696755 · 195 participants (planned) · Start Feb 3, 2026 · Primary completion Nov 2027
Drug: Icalcaprant; Placebo for Icalcaprant · For: Bipolar I Disorder; Bipolar II Disorder
Sites: Huntsville, Alabama; Chandler, Arizona; Tucson, Arizona · 33 sites in all
AbbVieAbbVie (ABBV)
NCT06722417 · 16 participants · Start Nov 26, 2024 · Primary completion Jan 17, 2025
Drug: Icalcaprant · For: Healthy Volunteer
Sites: Anaheim, California
AbbVieAbbVie (ABBV)
NCT06722430 · 12 participants · Start Nov 13, 2024 · Primary completion Jan 13, 2025
Drug: Icalcaprant; Itraconazole (ITZ) · For: Healthy Volunteer
Sites: Grayslake, Illinois
AbbVieAbbVie (ABBV)
NCT07219017 · 8 participants · Start Oct 15, 2025 · Primary completion Dec 9, 2025
Drug: ABBV-1354 · For: Healthy Volunteer
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Bipolar I Disorder
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- NBI-1117568Phase 35 trials
Neurocrine Biosciences · Schizophrenia, Bipolar I Disorder, Mania
- LB-102Phase 34 trials
LB Pharmaceuticals Inc. · Schizophrenia, Bipolar I Disorder
- OLZSAM, ALKS 3831Phase 32 trials
Alkermes, Inc. · Bipolar I Disorder, Schizophrenia
- ABBV-932Phase 23 trials
AbbVie · Bipolar I or II Disorder, Generalized Anxiety Disorder (GAD), Bipolar I Disorder
- AL-001lithium salicylate, L-proline cocrystalPhase 23 trials
Beijing Anlong Biopharmaceutical Co., Ltd. · Wet Age-related Macular Degeneration (wAMD), Bipolar I Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.